CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- 4 Planned sale Chief Financial Officer sold 1,882 shares at $18.15 ($34,162)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale President and COO sold 149 shares at $18.02 ($2,685)
- 144 Insider Sale of Securities
- 8-K Event Other events
- 4 Option exercise President and COO acquired 25,000 shares (option exercise)
- 4 Option exercise Chief Medical Officer acquired 19,789 shares (option exercise)
- 4 Planned sale Chief Financial Officer sold 9,200 shares at $18.31 ($168,492)
- 144 Insider Sale of Securities
- 4 Option exercise Chief Executive Officer acquired 29,500 shares (option exercise)
- 4 Planned sale President and COO sold 12,500 shares at $18.68 ($233,548)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure · Other events
- EFFECT Other Notice of Effectiveness
- 424B5 Offering Prospectus
- 4 Planned sale Chief Financial Officer sold 18,400 shares at an average $18.54 ($341,074)
- 4 Planned sale President and COO sold 12,500 shares at $18.05 ($225,588)
- 4 Planned sale Chief Executive Officer sold 41,163 shares at $18.86 ($776,429)
- 4 Planned sale Chief Medical Officer sold 11,000 shares at an average $18.65 ($205,108)
Page 7 of 14 · 266 filings